JP6021021B2 - 多発性嚢胞腎の検査方法および治療剤のスクリーニング方法 - Google Patents

多発性嚢胞腎の検査方法および治療剤のスクリーニング方法 Download PDF

Info

Publication number
JP6021021B2
JP6021021B2 JP2013537286A JP2013537286A JP6021021B2 JP 6021021 B2 JP6021021 B2 JP 6021021B2 JP 2013537286 A JP2013537286 A JP 2013537286A JP 2013537286 A JP2013537286 A JP 2013537286A JP 6021021 B2 JP6021021 B2 JP 6021021B2
Authority
JP
Japan
Prior art keywords
krtap4
cells
expression level
gene
mmp1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013537286A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013544089A5 (enExample
JP2013544089A (ja
Inventor
健二 長船
健二 長船
太郎 豊田
太郎 豊田
文彦 塩田
文彦 塩田
一和 中尾
一和 中尾
正勝 曽根
正勝 曽根
大輔 田浦
大輔 田浦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyoto University NUC
Original Assignee
Kyoto University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyoto University NUC filed Critical Kyoto University NUC
Publication of JP2013544089A publication Critical patent/JP2013544089A/ja
Publication of JP2013544089A5 publication Critical patent/JP2013544089A5/ja
Application granted granted Critical
Publication of JP6021021B2 publication Critical patent/JP6021021B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/135—Platelet-derived growth factor [PDGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/165—Vascular endothelial growth factor [VEGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Vascular Medicine (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2013537286A 2010-11-05 2011-11-07 多発性嚢胞腎の検査方法および治療剤のスクリーニング方法 Active JP6021021B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US41075710P 2010-11-05 2010-11-05
US61/410,757 2010-11-05
US201161530269P 2011-09-01 2011-09-01
US61/530,269 2011-09-01
PCT/JP2011/006203 WO2012060109A1 (en) 2010-11-05 2011-11-07 Method of examining polycystic kidney disease and method of screening for therapeutic agent of the disease

Publications (3)

Publication Number Publication Date
JP2013544089A JP2013544089A (ja) 2013-12-12
JP2013544089A5 JP2013544089A5 (enExample) 2014-12-25
JP6021021B2 true JP6021021B2 (ja) 2016-11-02

Family

ID=46024234

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013537286A Active JP6021021B2 (ja) 2010-11-05 2011-11-07 多発性嚢胞腎の検査方法および治療剤のスクリーニング方法

Country Status (4)

Country Link
US (1) US20130225443A1 (enExample)
EP (1) EP2635707B1 (enExample)
JP (1) JP6021021B2 (enExample)
WO (1) WO2012060109A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7838250B1 (en) 2006-04-04 2010-11-23 Singulex, Inc. Highly sensitive system and methods for analysis of troponin
EP2016394A4 (en) 2006-04-04 2013-04-24 Singulex Inc METHOD AND COMPOSITIONS FOR HIGHLY SENSITIVE ANALYSIS OF MARKERS AND DETECTION OF MOLECULES
AU2010259022B2 (en) 2009-06-08 2016-05-12 Singulex, Inc. Highly sensitive biomarker panels
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
PT3388075T (pt) 2015-03-27 2023-08-18 Immatics Biotechnologies Gmbh Novos péptidos e combinações de péptidos para uso em imunoterapia contra vários tumores
CN104771630A (zh) * 2015-04-07 2015-07-15 陆开云 一种治疗小儿疝气的药物
JP6621195B2 (ja) * 2015-07-17 2019-12-18 国立大学法人京都大学 多発性嚢胞腎の検査方法および治療剤のスクリーニング方法
US11116755B2 (en) * 2015-11-18 2021-09-14 Genzyme Corporation Biomarker of polycystic kidney disease and uses thereof
JP7176766B2 (ja) * 2017-11-17 2022-11-22 国立大学法人大阪大学 Ｃｄ３１陽性ｃｄ４５陰性ｃｄ２００陽性の哺乳動物細胞からなる細胞集団、およびその利用
KR102288447B1 (ko) * 2018-12-28 2021-08-10 서울대학교산학협력단 Ctgf 검출용 제제를 포함하는 다낭신의 진단용 조성물 및 이의 이용
KR102885974B1 (ko) * 2019-11-22 2025-11-13 서울대학교산학협력단 Metrnl 검출용 제제를 포함하는 다낭신의 진단용 조성물 및 이의 이용
KR102859441B1 (ko) * 2019-11-22 2025-09-12 서울대학교산학협력단 Opn 검출용 제제를 포함하는, 다낭신의 진단용 조성물 및 이의 이용
EP4185693A1 (en) * 2020-07-23 2023-05-31 Johann Wolfgang Goethe-Universität Frankfurt Combinatorial inhibition of transcription factors for treatment of heart failure
CN112798789A (zh) * 2020-12-08 2021-05-14 彭志勇 一种用于重症患者aki早期诊断的方法
CN112877275B (zh) * 2021-02-04 2023-03-31 中国农业科学院兰州兽医研究所 Hdac2基因敲除的bhk-21细胞系及其构建方法和应用
WO2023230339A1 (en) * 2022-05-26 2023-11-30 Yale University Method of treating, ameliorating and/or preventing polycystic kidney disease

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US20020103360A1 (en) 1998-09-01 2002-08-01 Yang Pan Novel protein related to melanoma-inhibiting protein and uses thereof
WO2002006529A2 (en) 2000-07-13 2002-01-24 The Johns Hopkins University School Of Medicine Detection and treatment of polycystic kidney disease
US6916619B2 (en) 2001-10-12 2005-07-12 Athena Diagnostics, Inc. Compositions and methods for genetic analysis of polycystic kidney disease
CA2872385C (en) * 2003-04-11 2019-01-15 Athena Diagnostics, Inc. Compositions and methods for genetic analysis of polycystic kidney disease
CN101233227A (zh) 2005-02-03 2008-07-30 国立大学法人冈山大学 由胚胎干细胞向肝细胞的分化诱导方法和由该方法诱导的肝细胞
JP2006239169A (ja) 2005-03-03 2006-09-14 Miyako Takagi 胚性幹細胞から分化誘導した腸管様細胞塊における壁内神経系の形成方法
JP5119430B2 (ja) 2005-04-08 2013-01-16 国立大学法人名古屋大学 多発性嚢胞腎疾患関連遺伝子及びその利用
US7709204B2 (en) * 2005-04-29 2010-05-04 Mayo Foundation For Medical Education And Research Assessing brain aneurysms
KR101420740B1 (ko) 2005-12-13 2014-07-17 교또 다이가꾸 핵초기화 인자
CA2644468C (en) 2006-03-02 2022-02-01 Cythera, Inc. Endocrine precursor cells, pancreatic hormone-expressing cells and methods of production
JP2010075631A (ja) 2008-09-29 2010-04-08 Japan Science & Technology Agency 未分化細胞から肝臓を分化誘導する方法
EP2376626A4 (en) 2008-12-13 2012-10-17 Dna Microarray MICRO-ENVIRONMENTAL NICHE ASSAY FOR SCREENING OF INDUCED PLURIPOTENT STEM CELLS (CIPS)

Also Published As

Publication number Publication date
US20130225443A1 (en) 2013-08-29
EP2635707A4 (en) 2014-04-30
JP2013544089A (ja) 2013-12-12
EP2635707A1 (en) 2013-09-11
EP2635707B1 (en) 2019-03-27
WO2012060109A1 (en) 2012-05-10

Similar Documents

Publication Publication Date Title
JP6021021B2 (ja) 多発性嚢胞腎の検査方法および治療剤のスクリーニング方法
Lee et al. The molecular profiles of neural stem cell niche in the adult subventricular zone
US10724097B2 (en) Methods and compositions for diagnosis and management of diabetes and metabolic syndrome
JP5924742B2 (ja) インフラマソームの活性を抑える薬剤をスクリーニングする方法
JP6143233B2 (ja) 運動ニューロン疾患の検査方法及び治療剤のスクリーニング方法
JP6143265B2 (ja) 人工多能性幹細胞の選別方法
US9846164B2 (en) Detection of human somatic cell reprogramming
JP6735490B2 (ja) 誘導神経細胞を用いたスクリーニング方法
JP6621195B2 (ja) 多発性嚢胞腎の検査方法および治療剤のスクリーニング方法
US10842822B2 (en) Diagnosis and treatment of parkinson's disease based on identification and amelioration of liver dysfunction
US12351830B2 (en) Method for maintaining and amplifying colon cancer stem cells and method for inducing colon cancer organoid
JP5807879B2 (ja) 人工多能性幹細胞の選択方法
KR102034929B1 (ko) Nckap1 단백질 또는 상기 단백질을 암호화하는 유전자를 포함하는 신경계 퇴행성질환의 예방 또는 치료용 약학적 조성물
JPWO2018207789A1 (ja) 疾患ｉＰＳ細胞を用いた神経毒性評価モデル系及びその使用
KR102175792B1 (ko) 줄기세포의 증식능을 탐지하기 위한 마커 및 이를 이용한 줄기세포의 고효율 증식방법
Rapicavoli et al. Research article The long noncoding RNA RNCR2 directs mouse retinal cell specification
Wang Ascl2 as a novel regulator of satellite cells

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141106

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141106

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151013

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151214

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160329

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160629

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20160707

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160830

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160923

R150 Certificate of patent or registration of utility model

Ref document number: 6021021

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250